These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

713 related articles for article (PubMed ID: 27009937)

  • 21. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
    Taieb J; Shi Q; Pederson L; Alberts S; Wolmark N; Van Cutsem E; de Gramont A; Kerr R; Grothey A; Lonardi S; Yoshino T; Yothers G; Sinicrope FA; Zaanan A; André T
    Ann Oncol; 2019 Sep; 30(9):1466-1471. PubMed ID: 31268130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype.
    Kwon Y; Park M; Jang M; Yun S; Kim WK; Kim S; Paik S; Lee HJ; Hong S; Kim TI; Min B; Kim H
    Oncotarget; 2017 Jun; 8(24):39367-39381. PubMed ID: 28455965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
    Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Piñol V; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Payá A; Alenda C;
    Gut; 2006 Jun; 55(6):848-55. PubMed ID: 16299036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.
    Sehdev A; Cramer HM; Ibrahim AA; Younger AE; O'Neil BH
    Discov Med; 2016 May; 21(117):341-7. PubMed ID: 27355330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.
    Ohrling K; Edler D; Hallström M; Ragnhammar P
    Acta Oncol; 2010 Aug; 49(6):797-804. PubMed ID: 20307245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients.
    Lanza G; Gafà R; Santini A; Maestri I; Guerzoni L; Cavazzini L
    J Clin Oncol; 2006 May; 24(15):2359-67. PubMed ID: 16710035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial.
    Smyth EC; Wotherspoon A; Peckitt C; Gonzalez D; Hulkki-Wilson S; Eltahir Z; Fassan M; Rugge M; Valeri N; Okines A; Hewish M; Allum W; Stenning S; Nankivell M; Langley R; Cunningham D
    JAMA Oncol; 2017 Sep; 3(9):1197-1203. PubMed ID: 28241187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic and predictive significance of microsatellite instability in stage II colorectal carcinoma: An 8-year study from a tertiary center in South India.
    Paulose RR; Ail DA; Biradar S; Vasudevan A; Sundaram KR
    Indian J Cancer; 2019; 56(4):302-308. PubMed ID: 31607697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implications of mismatch repair-deficient status on management of early stage colorectal cancer.
    Kawakami H; Zaanan A; Sinicrope FA
    J Gastrointest Oncol; 2015 Dec; 6(6):676-84. PubMed ID: 26697201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
    J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Multi-cohort Study of the Prognostic Significance of Microsatellite Instability or Mismatch Repair Status after Recurrence of Resectable Gastric Cancer.
    An JY; Choi YY; Lee J; Hyung WJ; Kim KM; Noh SH; Choi MG; Cheong JH
    Cancer Res Treat; 2020 Oct; 52(4):1153-1161. PubMed ID: 32599987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.
    Li P; Fang YJ; Li F; Ou QJ; Chen G; Ma G
    Br J Cancer; 2013 Apr; 108(6):1238-44. PubMed ID: 23481186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Routine testing for mismatch repair deficiency in sporadic colorectal cancer is justified.
    Ward RL; Turner J; Williams R; Pekarsky B; Packham D; Velickovic M; Meagher A; O'Connor T; Hawkins NJ
    J Pathol; 2005 Dec; 207(4):377-84. PubMed ID: 16175654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma.
    Elsaleh H; Iacopetta B
    Clin Colorectal Cancer; 2001 Aug; 1(2):104-9. PubMed ID: 12445368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnosis and management of DNA mismatch repair-deficient colorectal cancer.
    Stadler ZK
    Hematol Oncol Clin North Am; 2015 Feb; 29(1):29-41. PubMed ID: 25475571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microsatellite instability and colorectal cancer prognosis.
    Benatti P; Gafà R; Barana D; Marino M; Scarselli A; Pedroni M; Maestri I; Guerzoni L; Roncucci L; Menigatti M; Roncari B; Maffei S; Rossi G; Ponti G; Santini A; Losi L; Di Gregorio C; Oliani C; Ponz de Leon M; Lanza G
    Clin Cancer Res; 2005 Dec; 11(23):8332-40. PubMed ID: 16322293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Microsatellite instability. A new predictive marker (?)].
    Dietmaier W
    Pathologe; 2010 Oct; 31 Suppl 2():268-73. PubMed ID: 20824433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic and predictive relevance of microsatellite instability in colorectal cancer.
    Storojeva I; Boulay JL; Heinimann K; Ballabeni P; Terracciano L; Laffer U; Mild G; Herrmann R; Rochlitz C
    Oncol Rep; 2005 Jul; 14(1):241-9. PubMed ID: 15944796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Consequences of testing for mismatch repair deficiency of colorectal cancer in clinical practice.
    Leicher LW; Lammertink MHA; Offerman SR; Morreau H; de Jong MM; de Groot JWB; van Westreenen HL; Vasen HFA; de Vos Tot Nederveen Cappel WH
    Scand J Gastroenterol; 2018 May; 53(5):632-636. PubMed ID: 29161904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.